{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:15:03Z","timestamp":1786994103130,"version":"build-2736575974"},"reference-count":143,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.mehy.2019.109240","type":"journal-article","created":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T11:24:06Z","timestamp":1558351446000},"page":"109240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The gadolinium hypothesis for fibromyalgia and unexplained widespread chronic pain"],"prefix":"10.1016","volume":"129","author":[{"given":"Silvia Maria","family":"Lattanzio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2019.109240_b0005","first-page":"15","article-title":"Symptoms and signs in fibromyalgia syndrome","volume":"60","author":"Cassisi","year":"2008","journal-title":"Reumatismo"},{"key":"10.1016\/j.mehy.2019.109240_b0010","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.amjmed.2009.09.007","article-title":"Diagnosis and differential diagnosis of fibromyalgia","volume":"122","author":"Goldenberg","year":"2009","journal-title":"Am J med"},{"key":"10.1016\/j.mehy.2019.109240_b0015","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.amjmed.2009.09.008","article-title":"Pathophysiology of fibromyalgia","volume":"122","author":"Bradley","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.mehy.2019.109240_b0020","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11916-013-0356-5","article-title":"Worldwide epidemiology of fibromyalgia","volume":"17","author":"Queiroz","year":"2013","journal-title":"Curr Pain Headache Rep"},{"key":"10.1016\/j.mehy.2019.109240_b0025","first-page":"1","article-title":"EULAR revised recommendations for the management of fibromyalgia","author":"Macfarlane","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.mehy.2019.109240_b0030","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/AJP.0000000000000354","article-title":"Fibromyalgia and chronic pain syndromes. A white paper detailing current challenges in the field","volume":"32","author":"Arnold","year":"2016","journal-title":"Clin J Pain"},{"key":"10.1016\/j.mehy.2019.109240_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12891-016-1027-6","article-title":"Fibromyalgia-related costs and loss of productivity: a substantial societal burden","volume":"17","author":"Lacasse","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.mehy.2019.109240_b0040","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.23265","article-title":"Health economic consequences related to the diagnosis of fibromyalgia syndrome","volume":"58","author":"Annemans","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mehy.2019.109240_b0045","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.rbr.2016.10.004","article-title":"SLK. Prevalence of fibromyalgia: literature review update","volume":"57","author":"Marques","year":"2017","journal-title":"Rev Bras Reumatol"},{"key":"10.1016\/j.mehy.2019.109240_b0050","doi-asserted-by":"crossref","unstructured":"Greenfield S, Fitzcharles MA, Esdaile JM. Reactive fibromyalgia syndrome 35; (1992) 678\u2013681.","DOI":"10.1002\/art.1780350612"},{"key":"10.1016\/j.mehy.2019.109240_b0055","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/00002060-199411000-00005","article-title":"Post-traumatic fibromyalgia: A long term follow-up","volume":"73","author":"Waylonis","year":"1994","journal-title":"Am J Phys Med Rehabil"},{"key":"10.1016\/j.mehy.2019.109240_b0060","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/art.1780400310","article-title":"Increased rates of fibromyalgia following cervical spine injury","volume":"40","author":"Buskila","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mehy.2019.109240_b0065","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0049-0172(00)80009-8","article-title":"Trauma and fibromyalgia: Is there an association and what does it mean?","volume":"29","author":"White","year":"2000","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.mehy.2019.109240_b0070","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/rheumatology\/41.4.450","article-title":"A case\u2013control study examining the role of physical trauma in the onset of fibromyalgia syndrome","volume":"41","author":"Al-Allaf","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.mehy.2019.109240_b0075","first-page":"198","article-title":"Clinical experiences with post-traumatic fibromyalgia syndrome","volume":"86","author":"Romano","year":"1990","journal-title":"W V Med J"},{"key":"10.1016\/j.mehy.2019.109240_b0080","first-page":"11","article-title":"Post-traumatic complex regional pain syndrome: clinical features and epidemiology","volume":"12","author":"Ratti","year":"2015","journal-title":"Clin Cases Miner Bone Metabol"},{"key":"10.1016\/j.mehy.2019.109240_b0085","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/jmri.24787","article-title":"Basic MR relaxation mechanisms and contrast agent design","volume":"42","author":"De L\u00e9on-Rod\u0155\u0131guez","year":"2015","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.mehy.2019.109240_b0090","doi-asserted-by":"crossref","DOI":"10.1021\/bc049817y","article-title":"Next generation, high relaxivity gadolinium MRI agents","volume":"16","author":"Raymond","year":"2005","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/j.mehy.2019.109240_b0095","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1021\/cr00081a003","article-title":"Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design","volume":"87","author":"Lauffer","year":"1987","journal-title":"Chem Rev"},{"key":"10.1016\/j.mehy.2019.109240_b0100","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejrad.2008.01.023","article-title":"Extracellular gadolinium-based contrast media: an overview","volume":"66","author":"Bellin","year":"2008","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.mehy.2019.109240_b0105","unstructured":".US Food and Drug Administration. FDA briefing document: Gadolinium retention after gadolinium based contrast magnetic resonance imaging in patients with normal renal function. https:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/medicalimagingdrugsadvisorycommittee\/ucm572848.pdf (September 8, 2017)."},{"key":"10.1016\/j.mehy.2019.109240_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12325-015-0275-4","article-title":"25 years of contrast-enhanced MRI:developments, current challenges and future perspectives","volume":"33","author":"Lohrke","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.mehy.2019.109240_b0115","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2214\/ajr.142.3.619","article-title":"Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent","volume":"142","author":"Weinmann","year":"1984","journal-title":"AJR, Am. J Roentgenol"},{"key":"10.1016\/j.mehy.2019.109240_b0120","unstructured":"US Food and Drug Administration. Drug safety communication. FDA evaluating the risk of brain deposits with repeated use of gadolinium based contrast agents for magnetic resonance imaging (MRI) (2015)."},{"key":"10.1016\/j.mehy.2019.109240_b0125","unstructured":"US Food and Drug Administration. FDA drug safety communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings.https:\/\/www.fda.gov\/drugs\/drugsafety\/ucm589213.htm (2018)."},{"key":"10.1016\/j.mehy.2019.109240_b0130","unstructured":"EMA\u2019s final opinion confirms restrictions on use of linear gadolinium agents in body scans EMA\/457616\/2017 (21 July 2017)."},{"key":"10.1016\/j.mehy.2019.109240_b0135","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1472-8206.2006.00447.x","article-title":"Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review","volume":"20","author":"Idee","year":"2006","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.mehy.2019.109240_b0140","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/jmri.21135","article-title":"Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis","volume":"26","author":"Ersoy","year":"2007","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.mehy.2019.109240_b0145","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1002\/jmri.21966","article-title":"Primer on gadolinium chemistry","volume":"30","author":"Sherry","year":"2009","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.mehy.2019.109240_b0150","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.18388\/abp.2000_3963","article-title":"Toxicological and cytophysiological aspects of lanthanides action","volume":"47","author":"Pa\u0142asz","year":"2000","journal-title":"Acta Biochim Pol"},{"key":"10.1016\/j.mehy.2019.109240_b0155","series-title":"Biochmistry of the Lanthanides","author":"Evans","year":"1990"},{"key":"10.1016\/j.mehy.2019.109240_b0160","doi-asserted-by":"crossref","first-page":"C515","DOI":"10.1152\/ajpcell.1990.259.3.C515","article-title":"Gadolinium blocks low-threshold and high-threshold calcium currents in pituitary-cells","volume":"259","author":"Biagi","year":"1990","journal-title":"Am J Physiol (Cell. Physiol 28)"},{"key":"10.1016\/j.mehy.2019.109240_b0165","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1085\/jgp.95.4.679","article-title":"Blockade of current through single calcium channels by trivalent lanthanide cations. effect of ionic radius on the rates of ion entry and exit","volume":"95","author":"Lansman","year":"1990","journal-title":"J Gen Physiol"},{"key":"10.1016\/j.mehy.2019.109240_b0170","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1113\/jphysiol.1993.sp019835","article-title":"Block of current through T-type calcium channels by trivalent metal cations and nickel in neural rat and human cells","volume":"469","author":"Mlinar","year":"1993","journal-title":"J Physiol"},{"key":"10.1016\/j.mehy.2019.109240_b0175","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/PL00005002","article-title":"Lanthanides inhibit human noradrenaline, 5-hydroxytryptamine and dopamine transporters","volume":"355","author":"Bryan-Lluka","year":"1997","journal-title":"Naunyn Schmiedebergs. Arch Pharmacol"},{"key":"10.1016\/j.mehy.2019.109240_b0180","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s10495-016-1311-9","article-title":"Gadolinium induced effects on mammalian cell motility, adherence and chromatin structure","volume":"22","author":"Nagy","year":"2017","journal-title":"Apoptosis"},{"key":"10.1016\/j.mehy.2019.109240_b0185","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0005-2736(72)90323-9","article-title":"Effects of lanthanum and gadolinium ions on cardiac sarcoplasmic reticulum","volume":"282","author":"Krasnow","year":"1972","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.mehy.2019.109240_b0190","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/0306-4522(82)90019-7","article-title":"The gadolinium ion: a potent blocker of calcium channels and catecholamine release from cultured chromaffin cells","volume":"7","author":"Bourne","year":"1982","journal-title":"Neuroscience"},{"key":"10.1016\/j.mehy.2019.109240_b0195","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1139\/y72-089","article-title":"Effects of rare earths and yttrium on striated muscle and the neuromuscular junction","volume":"50","author":"Bowen","year":"1972","journal-title":"Can J Physiol Pharmacol"},{"issue":"Suppl I","key":"10.1016\/j.mehy.2019.109240_b0200","first-page":"85","article-title":"Exposure, metabolism, and toxicity of rare earths and related compounds","volume":"104","author":"Hirano","year":"1997","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.mehy.2019.109240_b0205","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1021\/ic200260r","article-title":"Revised ionic radii of lanthanoid(III) ions in aqueous solution","volume":"50","author":"D\u2019Angelo","year":"2011","journal-title":"Inorg Chem"},{"key":"10.1016\/j.mehy.2019.109240_b0210","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/BF00140484","article-title":"Distribution and excretion of lanthanides: comparison between europium salts and complexes","volume":"7","author":"Bingham","year":"1994","journal-title":"Biometals"},{"key":"10.1016\/j.mehy.2019.109240_b0215","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0304-3940(98)01017-9","article-title":"Lanthanides stimulate [3H]-tyramine binding in the rat striatum","volume":"261","author":"Vaccari","year":"1999","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.mehy.2019.109240_b0220","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1093\/ndt\/gfr085","article-title":"Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis\u2014an autopsy-based review","volume":"26","author":"Sanyal","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.mehy.2019.109240_b0225","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.juro.2008.05.005","article-title":"Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis","volume":"180","author":"Bhave","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.mehy.2019.109240_b0230","article-title":"Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis","volume":"56","author":"High","year":"2007","journal-title":"J Am Acd Dermatol"},{"key":"10.1016\/j.mehy.2019.109240_b0235","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/cmmi.1683","article-title":"High signal intensity in dentate nucleus and globus pallidus on unenhanced T1-weighted MR images in three patients with impaired renal function and vascular calcification","volume":"11","author":"Barbieri","year":"2016","journal-title":"Contrast Media Mol Imaging"},{"key":"10.1016\/j.mehy.2019.109240_b0240","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/cmmi.146","article-title":"Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications","volume":"2","author":"Thakral","year":"2007","journal-title":"Contrast Media Mol Imaging"},{"key":"10.1016\/j.mehy.2019.109240_b0245","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1056\/NEJMcpc0708697","article-title":"Koreishi AF. Case records of the Massachusetts General Hospital. Case 6\u20132008. a 46-year-old woman with renal failure and stiffness of the joints and skin","volume":"358","author":"Kay","year":"2008","journal-title":"NEJM"},{"key":"10.1016\/j.mehy.2019.109240_b0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171704","article-title":"The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity - a systematic review","volume":"12","author":"Olchowy","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.mehy.2019.109240_b0255","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.mri.2016.08.024","article-title":"Gadolinium deposition in the brain","volume":"34","author":"Kanda","year":"2016","journal-title":"Magn Res Imaging"},{"key":"10.1016\/j.mehy.2019.109240_b0260","doi-asserted-by":"crossref","DOI":"10.1007\/s00062-018-0678-0","article-title":"A review of the current evidence on gadolinium deposition in the brain","author":"Pullicino","year":"2018","journal-title":"Clin Neuroradiol"},{"key":"10.1016\/j.mehy.2019.109240_b0265","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10534-016-9931-7","article-title":"Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms","volume":"29","author":"Rogosnitzky","year":"2016","journal-title":"Biometals"},{"key":"10.1016\/j.mehy.2019.109240_b0270","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/RLI.0000000000000266","article-title":"High levels of gadolinium deposition in the skin of a patient with normal renal function","volume":"51","author":"Roberts","year":"2016","journal-title":"Invest Radiol"},{"key":"10.1016\/j.mehy.2019.109240_b0275","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/RLI.0000000000000252","article-title":"Macrocyclic and other non\u2013group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: preliminary results from 9 patients with normal renal function","volume":"51","author":"Murata","year":"2016","journal-title":"Invest Radiol"},{"key":"10.1016\/j.mehy.2019.109240_b0280","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/01.rli.0000112789.57341.01","article-title":"Comparison of Gd-DTPA-BMA (Omniscan) versus Gd-HPDO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy","volume":"39","author":"Gibby","year":"2004","journal-title":"Invest Radiol"},{"key":"10.1016\/j.mehy.2019.109240_b0285","doi-asserted-by":"crossref","unstructured":"White GW, Gibby WA, Tweedle MF. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HPDO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled mass spectroscopy. 41 (2006) 272\u2013278.","DOI":"10.1097\/01.rli.0000186569.32408.95"},{"key":"10.1016\/j.mehy.2019.109240_b0290","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1039\/b905145g","article-title":"Incorporation of excess gadolinium into human bone from medical contrast agents","volume":"1","author":"Darrah","year":"2009","journal-title":"Metallomics"},{"key":"10.1016\/j.mehy.2019.109240_b0295","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1148\/radiol.2015142690","article-title":"Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy","volume":"276","author":"Kanda","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.mehy.2019.109240_b0300","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.3109\/02841851.2010.515614","article-title":"Gadolinium released from MR contrast agents is deposited in brain tumors: in situ demonstration using scanning electron microscopy with energy dispersive X-ray spectroscopy","volume":"51","author":"Xia","year":"2010","journal-title":"Acta Radiol"},{"key":"10.1016\/j.mehy.2019.109240_b0305","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1148\/radiol.15150025","article-title":"Intracranial gadolinium deposition after contrast-enhanced MR imaging","volume":"275","author":"McDonald","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.mehy.2019.109240_b0310","first-page":"1","article-title":"Hyperintense dentate nuclei on T1-weighted MRI: relation to repeat gadolinium administration","author":"Adin","year":"2015","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.mehy.2019.109240_b0315","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1148\/radiol.14140364","article-title":"High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration","volume":"275","author":"Kanda","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.mehy.2019.109240_b0320","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/RLI.0000000000000206","article-title":"Increased signal intensity in the dentate nucleus on unenhanced T1-weighted images after gadobenate dimeglumine administration","volume":"50","author":"Weberling","year":"2015","journal-title":"Invest Radiol"},{"key":"10.1016\/j.mehy.2019.109240_b0325","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/RLI.0000000000000072","article-title":"Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation","volume":"49","author":"Errante","year":"2014","journal-title":"Invest Radiol"},{"key":"10.1016\/j.mehy.2019.109240_b0330","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.2016152864","article-title":"Extent of signal hyperintensity on unenhanced T1-weighted brain MR images after more than 35 administrations of linear gadolinium-based contrast agents","volume":"282","author":"Zhang","year":"2017","journal-title":"Radiology"},{"key":"10.1016\/j.mehy.2019.109240_b0335","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1148\/radiol.2015150337","article-title":"Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent","volume":"275","author":"Radbruch","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.mehy.2019.109240_b0340","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2214\/AJR.15.15327","article-title":"Signal change in the dentate nucleus on T1-weighted MR images after multiple administrations of gadopentetate dimeglumine versus gadobutrol","volume":"206","author":"Cao","year":"2016","journal-title":"AJR"},{"key":"10.1016\/j.mehy.2019.109240_b0345","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/RLI.0000000000000227","article-title":"High-signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted images: Evaluation of the macrocyclic gadolinium-based contrast agent gadobutrol","volume":"50","author":"Radbruch","year":"2015","journal-title":"Invest Radiol"},{"key":"10.1016\/j.mehy.2019.109240_b0350","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/RLI.0000000000000154","article-title":"Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast enhanced magnetic resonance examinations with no systemic interval therapy","volume":"50","author":"Quattrocchi","year":"2015","journal-title":"Invest Radiol"},{"key":"10.1016\/j.mehy.2019.109240_b0355","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00247-017-3874-1","article-title":"Signal intensity at unenhanced T1-weighted magnetic resonance in the globus pallidus and dentate nucleus after serial administrations of a macrocyclic gadolinium-based contrast agent in children","volume":"47","author":"Rossi-Espagnet","year":"2017","journal-title":"Pediatr Radiol"},{"key":"10.1016\/j.mehy.2019.109240_b0360","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.3174\/ajnr.A4891","article-title":"Pediatric patients demonstrate progressive T1-weighted hyperintensity in the dentate nucleus following multiple doses of gadolinium-based contrast agent","volume":"37","author":"Roberts","year":"2016","journal-title":"Am J Neuroradiol"},{"key":"10.1016\/j.mehy.2019.109240_b0365","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1148\/radiol.13131669","article-title":"High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: Relationship with increasing cumulative dose of a gadolinium based contrast material","volume":"270","author":"Kanda","year":"2014","journal-title":"Radiology"},{"key":"10.1016\/j.mehy.2019.109240_b0370","doi-asserted-by":"crossref","first-page":"e1637","DOI":"10.1542\/peds.2015-2222","article-title":"MRI brain signal intensity changes of a child during the course of 35 gadolinium contrast examinations","volume":"136","author":"Miller","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.mehy.2019.109240_b0375","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1148\/radiol.2016160356","article-title":"Pediatric brain: Repeated exposure to linear gadolinium-based contrast material is associated with increased signal intensity at unenhanced T1-weighted MR imaging","volume":"282","author":"Flood","year":"2017","journal-title":"Radiology"},{"key":"10.1016\/j.mehy.2019.109240_b0380","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2463\/mrms.mp.2016-0054","article-title":"T1 shortening in the cerebral cortex after multiple administrations of gadolinium-based contrast agents","volume":"16","author":"Khant","year":"2017","journal-title":"Magn Reson Med Sci"},{"key":"10.1016\/j.mehy.2019.109240_b0385","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/RLI.0000000000000318","article-title":"Presumed gadolinium toxicity in subjects with normal renal function a report of 4 cases","volume":"51","author":"Semelka","year":"2016","journal-title":"Invest Radiol"},{"key":"10.1016\/j.mehy.2019.109240_b0390","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.mri.2016.05.005","article-title":"Self-reported gadolinium toxicity: a survey of patients with chronic symptoms","volume":"34","author":"Burke","year":"2016","journal-title":"Magn Res Imaging"},{"key":"10.1016\/j.mehy.2019.109240_b0395","unstructured":"US Food and Drug Administration. FDA briefing document: Gadolinium retention after gadolinium based contrast magnetic resonance imaging in patients with normal renal function. (September 8,2017) pag 25\u201326."},{"key":"10.1016\/j.mehy.2019.109240_b0400","first-page":"565","article-title":"Plasma tryptophan and musculoskeletal pain in nonarticular rheumatism (\u201cfibrositis syndrome\u201d)","author":"Moldofsky","year":"1978","journal-title":"Pain"},{"key":"10.1016\/j.mehy.2019.109240_b0405","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0304-3940(98)00937-9","article-title":"Relationship of substance P, 5-hydroxyindole acetic acid and tryptophan in serum of fibromyalgia patients","volume":"259","author":"Schwarz","year":"1999","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.mehy.2019.109240_b0410","first-page":"158","article-title":"Serum amino acids in fibrositis\/fibromyalgia syndrome","volume":"19","author":"Russell","year":"1989","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.mehy.2019.109240_b0415","first-page":"458","article-title":"Serotonin concentration in serum of patients with generalized tendomyopathy (fibromyalgia) and chronic polyarthritis (abstract)","volume":"88","author":"Stratz","year":"1993","journal-title":"Med Klin"},{"key":"10.1016\/j.mehy.2019.109240_b0420","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/978-1-4615-0135-0_30","article-title":"Experimental evaluation of an altered tryptophan metabolism in fibromyalgia","author":"Schwarz","year":"2003","journal-title":"Dev Tryptophan Serotonin Metab"},{"key":"10.1016\/j.mehy.2019.109240_b0425","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2017.00198","article-title":"Fibromyalgia syndrome: a metabolic approach grounded in biochemistry for the remission of symptoms","volume":"4","author":"Lattanzio","year":"2017","journal-title":"Front Med"},{"key":"10.1016\/j.mehy.2019.109240_b0430","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/art.1780371106","article-title":"Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome","volume":"37","author":"Russell","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mehy.2019.109240_b0435","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0304-3959(88)90019-X","article-title":"Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis","volume":"32","author":"Vaeroy","year":"1988","journal-title":"Pain"},{"key":"10.1016\/j.mehy.2019.109240_b0440","first-page":"555","article-title":"Serotonin levels, pain threshold, and fibromyalgia symptoms in the general population (abstract)","volume":"24","author":"Wolfe","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.mehy.2019.109240_b0445","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0304-3959(00)00284-0","article-title":"Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways","volume":"87","author":"Larson","year":"2000","journal-title":"Pain"},{"key":"10.1016\/j.mehy.2019.109240_b0450","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1002\/art.24849","article-title":"Elevated insular glutamate in fibromyalgia is associated with experimental pain","volume":"60","author":"Harris","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mehy.2019.109240_b0455","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11916-007-0216-2","article-title":"Sensitization, glutamate, and the link between migraine and fibromyalgia","volume":"11","author":"Sarchielli","year":"2007","journal-title":"Curr. Pain Headache Rep"},{"key":"10.1016\/j.mehy.2019.109240_b0460","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1111\/j.1460-9568.2007.05623.x","article-title":"Fibromyalgia patients show an abnormal dopamine response to pain","volume":"25","author":"Wood","year":"2007","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.mehy.2019.109240_b0465","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jpain.2006.05.014","article-title":"Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: a pilot study","volume":"8","author":"Wood","year":"2007","journal-title":"J Pain"},{"key":"10.1016\/j.mehy.2019.109240_b0470","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jpain.2008.12.008","article-title":"Changes in gray matter density in fibromyalgia: Correlation with dopamine metabolism","volume":"10","author":"Wood","year":"2009","journal-title":"J Pain"},{"key":"10.1016\/j.mehy.2019.109240_b0475","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0950-3579(96)80022-7","article-title":"Neurohormonal perturbations in fibromyalgia","volume":"10","author":"Crofford","year":"1996","journal-title":"Baillieres Clin Rheumatol"},{"key":"10.1016\/j.mehy.2019.109240_b0480","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1090-3801(99)90185-4","article-title":"Elevated plasma levels of neuropeptide Y in female fibromyalgia patients","volume":"3","author":"Anderberg","year":"1999","journal-title":"Eur J Pain"},{"key":"10.1016\/j.mehy.2019.109240_b0485","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2474-12-245","article-title":"Systematic review with meta-analysis: cytokines in fibromyalgia syndrome","volume":"12","author":"Uceyler","year":"2011","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.mehy.2019.109240_b0490","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jneuroim.2015.11.011","article-title":"IL-8 and IL-6 primarily mediate the inflammatory response in fibromyalgia patients","volume":"290","author":"Mendieta","year":"2016","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.mehy.2019.109240_b0495","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s00296-012-2538-6","article-title":"Elevated serum high-sensitivity C reactive protein levels in fibromyalgia syndrome patients correlate with body mass index, interleukin-6, interleukin-8, erythrocyte sedimentation rate","volume":"33","author":"Xiao","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.mehy.2019.109240_b0500","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.imlet.2014.01.009","article-title":"Fibromyalgia and cytokines","volume":"161","author":"Rodriguez-Pinto","year":"2014","journal-title":"Immunol Lett"},{"key":"10.1016\/j.mehy.2019.109240_b0505","first-page":"1366","article-title":"Circulating cytokine levels compared to pain in patients with fibromyalgia - a prospective longitudinal study over 6 months","volume":"35","author":"Wang","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.mehy.2019.109240_b0510","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.clinbiochem.2009.02.025","article-title":"Altered aminoacid homeostasis in subject affected by fibromyalgia","volume":"42","author":"Bazzichi","year":"2009","journal-title":"Clin Biochem"},{"key":"10.1016\/j.mehy.2019.109240_b0515","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0165-1781(00)00204-3","article-title":"Serotonergic markers and lowered plasma branched-chain-amino acid concentrations in fibromyalgia","volume":"97","author":"Maes","year":"2000","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.mehy.2019.109240_b0520","doi-asserted-by":"crossref","DOI":"10.1186\/ar1982","article-title":"Alteration of serotonin transporter density and activity in fibromyalgia","volume":"8","author":"Bazzichi","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.mehy.2019.109240_b0525","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0163-7258(01)00144-9","article-title":"The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines","volume":"91","author":"Eisenhofer","year":"2001","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.mehy.2019.109240_b0530","doi-asserted-by":"crossref","DOI":"10.1002\/art.1780350509","article-title":"Cerebrospinal fluid biogenic amine metabolites in fibromyalgia\/fibrositis syndrome and rheumatoid arthritis","volume":"35","author":"Russell","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mehy.2019.109240_b0535","first-page":"1564","article-title":"Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia","volume":"26","author":"Giovenco","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.mehy.2019.109240_b0540","first-page":"165","article-title":"Magnesium deficiency in fibromyalgia syndrome (abstract)","volume":"4","author":"Romano","year":"1994","journal-title":"J Nutr Med"},{"key":"10.1016\/j.mehy.2019.109240_b0545","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s00296-008-0593-9","article-title":"The relationship between serum trace element levels and clinical parameters in patients with fibromyalgia","volume":"28","author":"Sendur","year":"2008","journal-title":"Rhematol Int"},{"key":"10.1016\/j.mehy.2019.109240_b0550","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.3346\/jkms.2011.26.10.1253","article-title":"Women with fibromyalgia have lower levels of calcium, magnesium, iron and manganese in hair mineral analysis","volume":"26","author":"Kim","year":"2011","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.mehy.2019.109240_b0555","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.clinbiochem.2008.06.012","article-title":"ATP, calcium and magnesium levels in platelets of patients with primary fibromyalgia","volume":"41","author":"Bazzichi","year":"2008","journal-title":"Clin Biochem"},{"key":"10.1016\/j.mehy.2019.109240_b0560","first-page":"1120","article-title":"Thyroid function in patients with Fibromyalgia Syndrome","volume":"19","author":"Neeck","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.mehy.2019.109240_b0565","first-page":"137","article-title":"Changes in intracellular calcium and magnesium ions in the physiopathology of the fibromyalgia syndrome","volume":"91","author":"Magaldi","year":"2000","journal-title":"Minerva Med"},{"key":"10.1016\/j.mehy.2019.109240_b0570","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1529\/biophysj.106.103333","article-title":"Zn2+ sensitivity of high- and low-voltage activated calcium channels","volume":"93","author":"Sun","year":"2007","journal-title":"Biophys J"},{"key":"10.1016\/j.mehy.2019.109240_b0575","doi-asserted-by":"crossref","first-page":"1388S","DOI":"10.1093\/jn\/130.5.1388S","article-title":"Zinc deficiency, malnutrition and the gastrointestinal tract","volume":"130","author":"Wapnir","year":"2000","journal-title":"J Nutr"},{"key":"10.1016\/j.mehy.2019.109240_b0580","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1148\/radiol.10100560","article-title":"Zinc transmetallation and gadolinium retention after MR imaging: case report","volume":"257","author":"Greenberg","year":"2010","journal-title":"Radiology"},{"key":"10.1016\/j.mehy.2019.109240_b0585","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.tiv.2010.05.004","article-title":"Gadolinium-promoted precipitation of calcium phosphate is associated with profibrotic activation of RAW 264.7 macrophages","volume":"24","author":"Gou","year":"2010","journal-title":"Toxicol in Vitro"},{"key":"10.1016\/j.mehy.2019.109240_b0590","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/art.24471","article-title":"Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents","volume":"60","author":"Wermuth","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mehy.2019.109240_b0595","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.dsi.2016.01.006","article-title":"Cutaneous findings in fibromyalgia syndrome and their effect on quality of life","volume":"34","author":"Erdogan","year":"2016","journal-title":"Dermatologica Sinica"},{"key":"10.1016\/j.mehy.2019.109240_b0600","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s10067-010-1474-7","article-title":"Abnormal overexpression of mastocytes in skin biopsies of fibromyalgia patients","volume":"29","author":"Blanco","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.mehy.2019.109240_b0605","first-page":"146","article-title":"Detection of interleukin 1\u03b2 (il-1\u03c8), IL-6, and tumor necrosis factor-alpha in skin of patients with fibromyalgia","volume":"30","author":"Salemi","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.mehy.2019.109240_b0610","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/path.2311","article-title":"Gadodiamide contrast agent \u2018activates\u2019 fibroblasts: a possible cause of nephrogenic systemic fibrosis","volume":"214","author":"Edward","year":"2008","journal-title":"J Pathol"},{"key":"10.1016\/j.mehy.2019.109240_b0615","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.berh.2012.07.008","article-title":"Nephrogenic systemic fibrosis: A systemic fibrosing disease resulting from gadolinium exposure","volume":"26","author":"Bernstein","year":"2012","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.mehy.2019.109240_b0620","first-page":"351","article-title":"Skeletal muscle abnormalities in patients with fibromyalgia","volume":"315","author":"Olsen","year":"1998","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.mehy.2019.109240_b0625","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jbspin.2005.03.022","article-title":"Is fibromyalgia a muscle disorder?","volume":"73","author":"Le Goff","year":"2006","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.mehy.2019.109240_b0630","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s11926-000-0053-3","article-title":"Evidence for metabolic abnormalities in the muscles of patients with fibromyalgia","volume":"2","author":"Park","year":"2000","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.mehy.2019.109240_b0635","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/03009748609092661","article-title":"Muscle biopsy in primary fibromyalgia. Light-microscopical and histochemical findings","volume":"15","author":"Bengtsson","year":"1986","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.mehy.2019.109240_b0640","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/rheumatology\/41.7.721","article-title":"The muscle in fibromyalgia","volume":"41","author":"Bengtsson","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.mehy.2019.109240_b0645","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/art.1780330203","article-title":"al MBY. The american college of rheumatology 1990. criteria for the classification of fibromyalgia. report of the multicenter criteria committee","volume":"33","author":"Wolfe","year":"1990","journal-title":"Arthritis Rheum"},{"issue":"suppl 3A","key":"10.1016\/j.mehy.2019.109240_b0650","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0002-9343(86)90866-1","article-title":"The clinical syndrome of fibrositis","volume":"81","author":"Wolfe","year":"1986","journal-title":"Am J Med"},{"key":"10.1016\/j.mehy.2019.109240_b0655","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1136\/ard.2002.004762","article-title":"Increased DNA fragmentation and ultrastructural changes in fibromyalgic muscle fibres","volume":"63","author":"Sprott","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.mehy.2019.109240_b0660","first-page":"1206","article-title":"Nephrogenic systemic fibrosis. Review of 370 biopsy-confirmed cases","volume":"4","author":"Zou","year":"2011","journal-title":"JACC: Cardiovasc Imaging"},{"key":"10.1016\/j.mehy.2019.109240_b0665","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.carj.2016.05.006","article-title":"Adverse reactions to contrast material: a Canadian update","volume":"68","author":"Morzycki","year":"2017","journal-title":"Can Assoc Radiol J"},{"key":"10.1016\/j.mehy.2019.109240_b0670","doi-asserted-by":"crossref","DOI":"10.1021\/acs.est.5b04322","article-title":"Increases in anthropogenic gadolinium anomalies and rare earth element concentrations in San Francisco Bay over a 20 year record","author":"Hatje","year":"2016","journal-title":"Environ Sci Technol"},{"key":"10.1016\/j.mehy.2019.109240_b0675","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.epsl.2007.06.016","article-title":"Contrasting behaviour of anthropogenic gadolinium and natural rare earth elements in estuaries and the gadolinium input into the North Sea","volume":"260","author":"Kulaksiz","year":"2007","journal-title":"Earth Planet Sci Lett"},{"key":"10.1016\/j.mehy.2019.109240_b0680","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.chemer.2006.01.002","article-title":"Anthropogenic gadolinium as a micropollutant in river waters in Pennsylvania and in lake Erie, northeastern United States","volume":"66","author":"Bau","year":"2006","journal-title":"Chem Erde"},{"key":"10.1016\/j.mehy.2019.109240_b0685","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.chemosphere.2009.01.036","article-title":"Positive gadolinium anomalies in wastewater treatment plant effluents and aquatic environment in the H\u0301erault watershed (South France)","volume":"75","author":"Rabiet","year":"2009","journal-title":"Chemosphere"},{"key":"10.1016\/j.mehy.2019.109240_b0690","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0012-821X(96)00127-6","article-title":"Anthropogenic origin of positive gadolinium anomalies in river waters","volume":"143","author":"Bau","year":"1996","journal-title":"Earth Planet Sci Lett"},{"key":"10.1016\/j.mehy.2019.109240_b0695","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.apgeochem.2011.06.011","article-title":"Anthropogenic gadolinium as a microcontaminant in tap water used as drinking water in urban areas and megacities","volume":"26","author":"Kulaksiz","year":"2011","journal-title":"Appl Geochem"},{"key":"10.1016\/j.mehy.2019.109240_b0700","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.epsl.2012.11.033","article-title":"Anthropogenic dissolved and colloid\/nanoparticle-bound samarium, lanthanum and gadolinium in the Rhine River and the impending destruction of the natural rare earth element distribution in rivers","volume":"362","author":"Kulaksiz","year":"2013","journal-title":"Earth Planet Sci Lett"},{"key":"10.1016\/j.mehy.2019.109240_b0705","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.chemosphere.2016.12.135","article-title":"Anthropogenic rare earth elements and their spatial distributions in the Han river South Korea","volume":"172","author":"Song","year":"2017","journal-title":"Chemosphere"},{"key":"10.1016\/j.mehy.2019.109240_b0710","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.actbio.2016.11.024","article-title":"Gadolinium accumulation in organs of Sprague-Dawley rats after implantation of a biodegradable magnesium-gadolinium alloy","volume":"48","author":"Myrissa","year":"2017","journal-title":"Acta Biomater"},{"key":"10.1016\/j.mehy.2019.109240_b0715","doi-asserted-by":"crossref","DOI":"10.3390\/nano6060109","article-title":"Gd-Si oxide nanoparticles as contrast agents in magnetic resonance imaging","volume":"6","author":"Cabrera-Garcia","year":"2016","journal-title":"Nanomaterials"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987719303263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987719303263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:15:43Z","timestamp":1759691743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987719303263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":143,"alternative-id":["S0306987719303263"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2019.109240","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The gadolinium hypothesis for fibromyalgia and unexplained widespread chronic pain","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2019.109240","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109240"}}